最新头条！智能手机处理器芯片市场稳步增长，预计2024年出货量达11.9亿

智能手机处理器芯片市场稳步增长，预计2024年出货量达11.9亿

上海 - 根据市场研究机构群智咨询发布的最新报告，预计2024年全球智能手机处理器芯片出货量将达到约11.9亿颗，环比增长约4%。这表明，尽管智能手机市场整体增速放缓，但处理器芯片市场仍保持着稳健增长态势。

报告分析指出，智能手机处理器芯片出货量增长的主要动力来自以下几个方面：

• 5G手机的普及: 随着5G网络的快速部署，5G手机的销量也在快速增长。而5G手机需要配备性能更强的处理器芯片，因此对处理器芯片的需求也随之增加。
• 新兴市场的需求增长: 在新兴市场，智能手机的普及率仍然较低，这为智能手机处理器芯片带来了巨大的增长潜力。
• 人工智能和物联网应用的兴起: 人工智能和物联网应用的兴起对智能手机处理器芯片提出了更高的性能要求，也推动了处理器芯片市场的发展。

报告还指出，从品牌格局来看，高通、联发科和苹果将继续占据智能手机处理器芯片市场的主导地位。预计2024年，高通、联发科和苹果的市场份额将分别达到33%、31%和26%。

关于群智咨询

群智咨询是一家全球领先的市场研究机构，专注于智能手机、平板电脑、可穿戴设备、智能家居等领域。群智咨询拥有强大的数据采集能力和分析能力，为客户提供准确、可靠的市场研究数据和咨询服务。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.